A Phase 1 interventional study of PF-07817883 and Placebo in Healthy, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.
Among the 69 studies in COVID-19 by Pfizer, this one is the 14th largest by enrollment of the 41 interventional ones that give a count, is one of 18 that started in 2022, is one of 25 in phase 1, and was the 36th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
Pfizer · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in United States, Bulgaria, Japan and 4 more countries
Ages 0–17
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 2020; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is close to the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 20 across the 41 interventional studies, 2,038 across the 28 observational. Of the 53 that completed or were terminated, 39 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
5 of the studies in COVID-19 by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in COVID-19 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also evaluate how much PF-07817883 gets into the body when taken as pill. We may study if people's diets can affect this study medicine. We may also examine how PF-07817883 is processed and removed by the human body. Finally, we may look into if PF-07817883 has potential to interact with midazolam.
Combined 6-part study. Part-1: Single Ascending dose Part-2: Multiple Ascending Dose Part-3: Relative bioavailability and food effect Part-4: Metabolism and Excretion Part-5: Drug-drug interaction with midazolam Part-6: Supratherapeutic exposure Part-1,2 and 6 are double blind, sponsor open and Part-3,4 and 5 are open label study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-07817883
Drug: PF-07817883
Drug: PF-07817883
Drug: PF-07817883
Optional dose levels
Drug: PF-07817883
Optional dose levels
Drug: PF-07817883
A single dose of placebo
Drug: Placebo
DR=Dosing regimen; twice a day
Drug: PF-07817883
Drug: PF-07817883
Optional dosing regimen
Drug: PF-07817883
Optional dosing regimen
Drug: PF-07817883
Optional dosing regimen to be studied in Japanese population
Drug: PF-07817883
Optional dosing regimen to be studied in Chinese population
Drug: PF-07817883
Drug: Placebo
PART-3 is optional
Drug: PF-07817883
First solid oral formulation (FORM1)
Drug: PF-07817883
Second solid oral formulations (FORM-2) is optional
Drug: PF-07817883
Drug: PF-07817883
Drug: PF-07817883
PART-4 is optional
Drug: PF-07817883
Single dose of 5 mg alone
Drug: Midazolam
Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883
Drug: PF-07817883 · Drug: Midazolam
A single dose at supratherapeutic exposure administered as divided doses (1h apart)
Drug: PF-07817883
A single dose of placebo administered as divided doses (1h apart)
Drug: Placebo
Moxifloxacin 400 mg at 0h followed by placebo at 1h
Drug: Placebo · Drug: Moxifloxacin
Oral suspension or solid oral formulation(s)
Placebo suspension
midazolam oral solution
Moxifloxacin 400 mg tablet
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)
Part 1: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: (lymphocytes less than (\<) 0.8\*lower limit of normal \[LLN\] \[10\^3 per millimeter cube {mm3}\], lymphocytes/leukocytes \<0.8\*LLN \[percentage {%}\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes greater than (\>) 1.2\*upper limit of normal \[ULN\] \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[milliequivalents per liter {mEq/L}\], creatine kinase \>2.0\*ULN \[units per liter {U/L}\], lipase \>1.5\*ULN \[U/L\]), and urinalysis (urine hemoglobin greater than or equal to \[\>=\] 1, leukocyte esterase \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 beats per minute (bpm), value \> 120 bpm.
Time frame: Up to Day 2 of each period
Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: Up to Day 2 of each period
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)
Part 2: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: hematology (lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (urate \>1.2\*ULN \[milligrams per deciliter\] {mg/dL}), and urinalysis (ketones \>=1, urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)
Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.
Time frame: Up to Day 12
Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: Up to Day 12
Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension
Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension
Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 4: Percentage of Total Dose Administered Recovered in Urine
The percentage of total dose administered recovered in urine was reported in this outcome measure.
Time frame: Up to 144 hours post-dose
Part 4: Percentage of Total Dose Administered Recovered in Feces
The percentage of total dose administered recovered in feces was reported in this outcome measure.
Time frame: Up to 144 hours post-dose
Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces
The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.
Time frame: Up to 144 hours post-dose
Part 5: Maximum Observed Concentration (Cmax) of Midazolam
Cmax of midazolam was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam
AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 6: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)
Part 6: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: hematology (lymphocytes \<0.6\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], basophils/leukocytes \>1.2\*ULN \[%\], eosinophils/leukocytes \>1.2\*ULN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\], prothrombin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[mEq/L\], creatine kinase \> 2.0\*ULN \[U/L\], lipase \> 1.5\*ULN \[U/L\], urobilinogen \>=1 \[ehrlich units/deciliter\] {EU/dL}) and urinalysis (urine hemoglobin \>=1, leukocyte esterase \>=1, ketones \>=1, bacteria \>20 \[per low power field\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
Time frame: Up to Day 6 of each period
Part 6: Number of Participants According to Categorization of ECG Data
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \< value \<= 480 msec and QTcF interval, aggregate 30 msec \< change \<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: Up to Day 6 of each period
Part 1: Maximum Observed Concentration (Cmax) of PF-07817883
Cmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Time for Cmax (Tmax) of PF-07817883
Tmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883
Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883
AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883
AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Terminal Half-Life (t1/2) of PF-07817883
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 1: Apparent Clearance (CL/F) of PF-07817883
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10
Cmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10
Tmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10
AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.
Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10
C12 of PF-07817883 was reported in this outcome measure.
Time frame: 12 hours on Day 5 and Day 10
Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10
Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.
Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10
AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.
Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10
Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.
Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10
Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.
Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10
Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.
Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10
PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.
Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
Time frame: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10
Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\*urine concentration) for each collection over the dosing interval.
Time frame: Day 10 (0 to 12 hours)
Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10
Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\*Aetau/dose.
Time frame: Day 10 (0 to 12 hours)
Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10
CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.
Time frame: Day 10 (0 to 12 hours)
Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition
Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition
Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Time for Cmax (Tmax) of PF-07817883
Tmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Maximum Observed Concentration (Cmax) of PF-07817883
Cmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Terminal Half-Life (t1/2) of PF-07817883
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Apparent Clearance (CL/F) of PF-07817883
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Part 3: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)
Part 3: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: hematology (monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]) and urinalysis (urine hemoglobin \>=1, bacteria \>20 \[/lpf\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)
Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.
Time frame: Up to Day 3 of each period
Part 3: Number of Participants With ECG Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: Up to Day 3 of each period
Part 4: Time for Cmax (Tmax) of PF-07817883
Tmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Maximum Observed Concentration (Cmax) of PF-07817883
Cmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Terminal Half-Life (t1/2) of PF-07817883
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Apparent Clearance (CL/F) of PF-07817883
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Part 4: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)
Part 4: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: hematology (mean corpuscular volume \<0.9\*LLN \[cubic micrometer {um\^3}\], mean corpuscular hemoglobin \<0.9\*LLN \[picograms per cell {pg/cell}\], monocytes/leukocytes \>1.2\*ULN \[%\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
Time frame: Up to Day 11
Part 4: Number of Participants With ECG Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: Up to Day 11
Part 5: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Part 5: Number of Participants With Laboratory Test Abnormalities
Laboratory parameters included: hematology (lymphocytes \<0.8\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \<0.8\*LLN \[%\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (amylase \>1.5\*ULN \[units/liter\] {U/L}), and urinalysis (urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Part 5: Number of Participants With ECG Abnormalities
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Part 5: Time for Cmax (Tmax) of Midazolam
Tmax of midazolam was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam
AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 5: Terminal Half-Life (t1/2) of Midazolam
t1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 5: Apparent Clearance (CL/F) of Midazolam
CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam
Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Part 6: Maximum Observed Concentration (Cmax) of PF-07817883
Cmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Part 6: Time for Cmax (Tmax) of PF-07817883
Tmax of PF-07817883 was reported in this outcome measure.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Part 6: Terminal Half-Life (t1/2) of PF-07817883
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 1 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 1 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 1 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 1 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 1 | 2 | 1 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 4 | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 3 | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 4 | 4 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 4 | 4 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | Placebo (Suspension), Fasted | Placebo (Suspension), Fed | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 | 1 | 2 | 1 | 0 | 3 | 0 | 1 |
Laboratory parameters included: (lymphocytes less than (\<) 0.8\*lower limit of normal \[LLN\] \[10\^3 per millimeter cube {mm3}\], lymphocytes/leukocytes \<0.8\*LLN \[percentage {%}\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes greater than (\>) 1.2\*upper limit of normal \[ULN\] \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[milliequivalents per liter {mEq/L}\], creatine kinase \>2.0\*ULN \[units per liter {U/L}\], lipase \>1.5\*ULN \[U/L\]), and urinalysis (urine hemoglobin greater than or equal to \[\>=\] 1, leukocyte esterase \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | Placebo (Suspension), Fasted | Placebo (Suspension), Fed | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Laboratory Test Abnormalities | 5 | 1 | 2 | 2 | 1 | 1 | 2 | 2 |
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 beats per minute (bpm), value \> 120 bpm.
| Participants | Placebo (Suspension), Fasted | Placebo (Suspension), Fed | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|---|---|
| SBP value < 90 mmHg | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| SBP Change >= 30 mmHg increase | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| SBP Change >= 30 mmHg decrease | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| DBP Value < 50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP Change >= 20 mmHg increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP Change >= 20 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR Value < 40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR Value > 120 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | Placebo (Suspension), Fasted | Placebo (Suspension), Fed | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 2 | 1 | 0 | 2 | 0 | 2 |
Laboratory parameters included: hematology (lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (urate \>1.2\*ULN \[milligrams per deciliter\] {mg/dL}), and urinalysis (ketones \>=1, urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Laboratory Test Abnormalities | 1 | 2 | 2 | 2 | 0 | 1 |
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.
| Participants | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria | 0 | 0 | 0 | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 |
Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.
| Nanogram*Hour per milliliter (ng*hr/mL) | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| AUCinf | 42970 ± 35 | 44140 ± 38 | 28430 ± 28 | 42930 ± 43 | 46170 ± 27 |
| AUClast | 42540 ± 35 | 43570 ± 37 | 27750 ± 29 | 41620 ± 41 | 35930 ± 54 |
Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.
| Nanogram per milliliter (ng/mL) | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension | 9354 ± 18 | 6934 ± 35 | 4590 ± 21 | 6284 ± 38 | 5008 ± 47 |
The percentage of total dose administered recovered in urine was reported in this outcome measure.
| Percentage dose excreted | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Percentage of Total Dose Administered Recovered in Urine | 12.6 ± 4.7 |
The percentage of total dose administered recovered in feces was reported in this outcome measure.
| Percentage dose excreted | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Percentage of Total Dose Administered Recovered in Feces | 88.9 ± 10 |
The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.
| Percentage dose excreted | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces | 101.5 ± 7.7 |
Cmax of midazolam was reported in this outcome measure.
| Nanogram per milliliter (ng/mL) | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Maximum Observed Concentration (Cmax) of Midazolam | 33.71 ± 34 | 30.20 ± 28 |
AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
| Nanogram*Hour per milliliter (ng*hr/mL) | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam | 94.30 ± 26 | 79.85 ± 31 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | Placebo (Suspension), Fasted | PF-07817883 6000 mg (Suspension), Fasted | Moxifloxacin 400 mg, Fasted |
|---|---|---|---|
| Part 6: Number of Participants With TEAEs | 4 | 6 | 4 |
Laboratory parameters included: hematology (lymphocytes \<0.6\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], basophils/leukocytes \>1.2\*ULN \[%\], eosinophils/leukocytes \>1.2\*ULN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\], prothrombin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[mEq/L\], creatine kinase \> 2.0\*ULN \[U/L\], lipase \> 1.5\*ULN \[U/L\], urobilinogen \>=1 \[ehrlich units/deciliter\] {EU/dL}) and urinalysis (urine hemoglobin \>=1, leukocyte esterase \>=1, ketones \>=1, bacteria \>20 \[per low power field\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | Placebo (Suspension), Fasted | PF-07817883 6000 mg (Suspension), Fasted | Moxifloxacin 400 mg, Fasted |
|---|---|---|---|
| Part 6: Number of Participants With Laboratory Test Abnormalities | 12 | 12 | 7 |
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
| Participants | Placebo (Suspension), Fasted | PF-07817883 6000 mg (Suspension), Fasted | Moxifloxacin 400 mg, Fasted |
|---|---|---|---|
| SBP value < 90 mmHg | 1 | 2 | 3 |
| SBP change >= 30 mmHg increase | 0 | 1 | 0 |
| SBP change >= 30 mmHg decrease | 0 | 0 | 0 |
| DBP value < 50 mmHg | 0 | 0 | 0 |
| DBP change >= 20 mmHg increase | 0 | 0 | 0 |
| DBP change >= 20 mmHg decrease | 0 | 0 | 1 |
| Pulse rate value < 40 bpm | 0 | 0 | 0 |
| Pulse rate value > 120 bpm | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \< value \<= 480 msec and QTcF interval, aggregate 30 msec \< change \<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | Placebo (Suspension), Fasted | PF-07817883 6000 mg (Suspension), Fasted | Moxifloxacin 400 mg, Fasted |
|---|---|---|---|
| QTCF interval, aggregate 450 msec < Value <= 480 msec | 0 | 0 | 1 |
| QTCF interval, aggregate 30 msec < Change <= 60 msec | 0 | 0 | 1 |
Cmax of PF-07817883 was reported in this outcome measure.
| Nanogram per milliliter (ng/mL) | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Maximum Observed Concentration (Cmax) of PF-07817883 | 2269 ± 51 | 6235 ± 20 | 3223 ± 13 | 17420 ± 36 | 34420 ± 12 | 34670 ± 36 |
Tmax of PF-07817883 was reported in this outcome measure.
| Hours | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Time for Cmax (Tmax) of PF-07817883 | 1.00 (0.500 to 1.50) | 0.792 (0.500 to 1.50) | 1.25 (1.00 to 2.00) | 0.500 (0.500 to 1.00) | 0.500 (0.500 to 1.05) | 1.00 (0.550 to 1.50) |
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
| Nanogram*hour per milliliter | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883 | 10890 ± 47 | 34580 ± 25 | 27080 ± 25 | 83490 ± 36 | 160700 ± 33 | 185700 ± 17 |
Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.
| Nanogram per milliliter per milligram | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 | 15.14 ± 51 | 12.48 ± 19 | 6.445 ± 13 | 11.61 ± 36 | 11.49 ± 12 | 8.672 ± 36 |
AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.
| Nanogram*hour/milliliter/milligram | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883 | 72.61 ± 47 | 69.17 ± 25 | 54.16 ± 25 | 55.64 ± 35 | 53.53 ± 33 | 46.43 ± 17 |
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
| Nanogram*hour/milliliter (ng*hr/mL) | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883 | 11250 ± 53 | 35950 ± 25 | 28120 ± 28 | 85320 ± 34 | 166100 ± 34 | 189400 ± 19 |
AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.
| Nanogram*hour/milliliter/milligram | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883 | 74.99 ± 53 | 71.81 ± 25 | 56.23 ± 28 | 56.86 ± 34 | 55.33 ± 35 | 47.34 ± 19 |
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Terminal Half-Life (t1/2) of PF-07817883 | 4.534 ± 0.50659 | 13.88 ± 10.838 | 15.95 ± 8.4657 | 10.84 ± 6.1747 | 18.79 ± 14.234 | 13.05 ± 7.3974 |
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).
| Liter (L) | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883 | 86.87 ± 48 | 209.5 ± 101 | 366.1 ± 50 | 242.9 ± 80 | 367.4 ± 87 | 358.7 ± 44 |
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
| Liter per hour (L/hr) | PF-07817883 150 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fasted | PF-07817883 500 mg (Suspension), Fed | PF-07817883 1500 mg (Suspension), Fasted | PF-07817883 3000 mg (Suspension), Fasted | PF-07817883 4000 mg (Suspension), Fasted |
|---|---|---|---|---|---|---|
| Part 1: Apparent Clearance (CL/F) of PF-07817883 | 13.33 ± 53 | 13.93 ± 25 | 17.79 ± 28 | 17.58 ± 35 | 18.09 ± 35 | 21.13 ± 19 |
Cmax of PF-07817883 was reported in this outcome measure.
| Nanogram/milliliter | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 1 | 3582 ± 20 | 8470 ± 39 | 24100 ± 22 | 8381 ± 12 |
| Day 5 | 4234 ± 7 | 9112 ± 14 | 27530 ± 22 | 8260 ± 18 |
| Day 10 | 3492 ± 15 | 7852 ± 21 | 23420 ± 14 | 7306 ± 25 |
Tmax of PF-07817883 was reported in this outcome measure.
| Hours | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 1 | 0.759 (0.500 to 1.00) | 0.775 (0.500 to 1.00) | 0.500 (0.500 to 1.50) | 1.00 (1.00 to 1.05) |
| Day 5 | 0.859 (0.500 to 1.02) | 0.500 (0.500 to 0.500) | 0.500 (0.500 to 1.00) | 0.500 (0.500 to 1.00) |
| Day 10 | 0.500 (0.500 to 1.00) | 0.500 (0.500 to 1.00) | 0.500 (0.500 to 0.500) | 0.533 (0.500 to 1.00) |
AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.
| Nanogram*hour per milliliter (ng*hr/mL) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 1 | 14760 ± 26 | 36440 ± 27 | 108400 ± 15 | 36880 ± 22 |
| Day 5 | 18460 ± 15 | 36300 ± 10 | 114000 ± 22 | 37680 ± 29 |
| Day 10 | 17180 ± 10 | 34960 ± 8 | 103900 ± 18 | 34650 ± 29 |
C12 of PF-07817883 was reported in this outcome measure.
| Nanogram per milliliter (ng/mL) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 389.3 ± 15 | 734.5 ± 15 | 2598 ± 47 | 716.0 ± 47 |
| Day 10 | 425.7 ± 12 | 865.9 ± 22 | 2315 ± 35 | 585.5 ± 28 |
Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.
| Nanogram/milliliter/milligram (ng/mL/mg) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 1 | 17.93 ± 20 | 14.15 ± 39 | 16.07 ± 22 | 14.00 ± 12 |
| Day 5 | 21.18 ± 7 | 15.20 ± 13 | 18.35 ± 22 | 13.76 ± 18 |
| Day 10 | 17.47 ± 15 | 13.07 ± 21 | 15.61 ± 14 | 12.20 ± 25 |
AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.
| Nanogram*hour/milliliter/milligram | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 1 | 73.94 ± 26 | 60.70 ± 27 | 72.25 ± 15 | 61.44 ± 22 |
| Day 5 | 92.46 ± 15 | 60.49 ± 10 | 76.20 ± 23 | 62.82 ± 29 |
| Day 10 | 86.04 ± 10 | 58.28 ± 8 | 69.43 ± 18 | 57.78 ± 29 |
Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.
| Nanogram/milliliter (ng/mL) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 1542 ± 15 | 3022 ± 10 | 9515 ± 22 | 3140 ± 29 |
| Day 10 | 1434 ± 10 | 2914 ± 8 | 8672 ± 18 | 2890 ± 29 |
Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.
| Ratio | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 1.250 ± 28 | 0.9972 ± 18 | 1.054 ± 9 | 1.022 ± 7 |
| Day 10 | 1.163 ± 18 | 0.8962 ± 20 | 0.9605 ± 4 | 0.9412 ± 8 |
Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.
| Ratio | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 1.183 ± 22 | 1.075 ± 30 | 1.142 ± 33 | 0.9844 ± 18 |
| Day 10 | 0.9744 ± 20 | 0.8471 ± 36 | 0.9717 ± 18 | 0.8712 ± 21 |
PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.
| Ratio | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 10.88 ± 10 | 13.47 ± 21 | 10.60 ± 49 | 13.22 ± 10 |
| Day 10 | 8.566 ± 14 | 11.05 ± 30 | 10.13 ± 23 | 12.46 ± 9 |
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
| Liter/hour (L/hr) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Day 5 | 10.83 ± 15 | 16.57 ± 10 | 13.12 ± 22 | 15.88 ± 29 |
| Day 10 | 11.60 ± 10 | 17.13 ± 8 | 14.37 ± 18 | 17.32 ± 29 |
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
| Liter | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10 | 200.1 ± 84 | 279.6 ± 62 | 198.1 ± 98 | 186.0 ± 115 |
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10 | 13.95 ± 9.3938 | 13.01 ± 8.8563 | 11.44 ± 6.8367 | 8.587 ± 5.8524 |
Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\*urine concentration) for each collection over the dosing interval.
| Milligram (mg) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10 | 18.47 ± 16 | 96.86 ± 5 | 373.2 ± 10 | 85.85 ± 20 |
Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\*Aetau/dose.
| Percentage of Dose Excreted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10 | 9.261 ± 16 | 16.15 ± 5 | 24.90 ± 10 | 14.34 ± 20 |
CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.
| Liter/hour (L/hr) | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese |
|---|---|---|---|---|
| Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10 | 1.074 ± 20 | 2.771 ± 5 | 3.586 ± 26 | 2.477 ± 51 |
Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.
| Nanogram*Hour per milliliter (ng*hr/mL) | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|
| AUCinf | 44140 ± 38 | 28430 ± 28 | 42930 ± 43 | 46170 ± 27 |
| AUClast | 43570 ± 37 | 27750 ± 29 | 41620 ± 41 | 35930 ± 54 |
Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.
| Nanogram per milliliter (ng/mL) | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|
| Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition | 6934 ± 35 | 4590 ± 21 | 6284 ± 38 | 5008 ± 47 |
Tmax of PF-07817883 was reported in this outcome measure.
| Hours | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Time for Cmax (Tmax) of PF-07817883 | 0.750 (0.500 to 1.05) | 1.01 (0.500 to 2.00) | 4.00 (1.00 to 4.00) | 1.34 (1.00 to 2.00) | 4.00 (2.00 to 6.00) |
Cmax of PF-07817883 was reported in this outcome measure.
| Nanogram/milliliter (ng/mL) | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Maximum Observed Concentration (Cmax) of PF-07817883 | 9354 ± 18 | 6934 ± 35 | 4590 ± 21 | 6284 ± 38 | 5008 ± 47 |
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
| Nanogram*hour/milliliter (ng*hr/mL) | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883 | 42540 ± 35 | 43570 ± 37 | 27750 ± 29 | 41620 ± 41 | 35930 ± 54 |
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
| Nanogram*hour/milliliter (ng*hr/mL) | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883 | 42970 ± 35 | 44140 ± 38 | 28430 ± 28 | 42930 ± 43 | 46170 ± 27 |
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Terminal Half-Life (t1/2) of PF-07817883 | 7.578 ± 3.2536 | 7.957 ± 3.8740 | 10.15 ± 2.2890 | 6.822 ± 3.5964 | 11.07 ± 4.4518 |
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
| Liter/hour | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Apparent Clearance (CL/F) of PF-07817883 | 13.97 ± 35 | 13.58 ± 38 | 21.09 ± 28 | 13.98 ± 43 | 12.98 ± 27 |
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
| Liter | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883 | 136.2 ± 55 | 136.7 ± 50 | 302.2 ± 31 | 120.7 ± 55 | 192.8 ± 64 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Number of Participants With TEAEs | 4 | 1 | 1 | 4 | 2 |
Laboratory parameters included: hematology (monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]) and urinalysis (urine hemoglobin \>=1, bacteria \>20 \[/lpf\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Number of Participants With Laboratory Test Abnormalities | 0 | 0 | 2 | 0 | 2 |
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.
| Participants | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria | 0 | 0 | 0 | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed |
|---|---|---|---|---|---|
| Part 3: Number of Participants With ECG Abnormalities | 0 | 0 | 0 | 0 | 0 |
Tmax of PF-07817883 was reported in this outcome measure.
| Hours | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Time for Cmax (Tmax) of PF-07817883 | 0.500 (0.500 to 2.00) |
Cmax of PF-07817883 was reported in this outcome measure.
| Nanogram/milliliter (ng/mL) | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Maximum Observed Concentration (Cmax) of PF-07817883 | 6791 ± 35 |
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
| Nanogram*hour/milliliter (ng*hr/mL) | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883 | 35520 ± 24 |
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
| Nanogram*hour/milliliter (ng*hr/mL) | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883 | 36910 ± 26 |
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Terminal Half-Life (t1/2) of PF-07817883 | 6.882 ± 3.0621 |
CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
| Liter/hour | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Apparent Clearance (CL/F) of PF-07817883 | 16.26 ± 26 |
Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).
| Liter | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883 | 146.7 ± 36 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Number of Participants With TEAEs | 4 |
Laboratory parameters included: hematology (mean corpuscular volume \<0.9\*LLN \[cubic micrometer {um\^3}\], mean corpuscular hemoglobin \<0.9\*LLN \[picograms per cell {pg/cell}\], monocytes/leukocytes \>1.2\*ULN \[%\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Number of Participants With Laboratory Test Abnormalities | 1 |
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
| Participants | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| SBP value < 90 mmHg | 1 |
| SBP change >= 30 mmHg increase | 0 |
| SBP change >= 30 mmHg decrease | 0 |
| DBP value < 50 mmHg | 1 |
| DBP change >= 20 mmHg increase | 0 |
| DBP change >= 20 mmHg decrease | 0 |
| Pulse rate value < 40 bpm | 0 |
| Pulse rate value > 120 bpm | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | Part 4: PF-07817883 600 mg (Suspension), Fasted |
|---|---|
| Part 4: Number of Participants With ECG Abnormalities | 0 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.
| Participants | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Number of Participants With TEAEs | 11 | 10 |
Laboratory parameters included: hematology (lymphocytes \<0.8\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \<0.8\*LLN \[%\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (amylase \>1.5\*ULN \[units/liter\] {U/L}), and urinalysis (urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.
| Participants | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Number of Participants With Laboratory Test Abnormalities | 5 | 2 |
Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.
| Participants | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| SBP value < 90 mmHg | 3 | 3 |
| SBP change >= 30 mmHg increase | 0 | 0 |
| SBP change >= 30 mmHg decrease | 0 | 1 |
| DBP value < 50 mmHg | 2 | 2 |
| DBP change >= 20 mmHg increase | 0 | 0 |
| DBP change >= 20 mmHg decrease | 0 | 0 |
| Pulse rate value < 40 bpm | 0 | 0 |
| Pulse rate value > 120 bpm | 0 | 0 |
Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.
| Participants | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Number of Participants With ECG Abnormalities | 0 | 0 |
Tmax of midazolam was reported in this outcome measure.
| Hours | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Time for Cmax (Tmax) of Midazolam | 0.500 (0.500 to 1.12) | 0.500 (0.500 to 1.02) |
AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
| Nanogram*hour/milliliter (ng*hr/mL) | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam | 92.37 ± 27 | 77.46 ± 32 |
t1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Terminal Half-Life (t1/2) of Midazolam | 6.589 ± 1.6566 | 6.923 ± 1.9185 |
CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.
| Liter/hour | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Apparent Clearance (CL/F) of Midazolam | 53.02 ± 26 | 62.60 ± 31 |
Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).
| Liter | PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Midazolam 5 mg |
|---|---|---|
| Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam | 488.5 ± 44 | 598.9 ± 45 |
Cmax of PF-07817883 was reported in this outcome measure.
| Nanogram/milliliter (ng/mL) | PF-07817883 6000 mg (Suspension), Fasted |
|---|---|
| Part 6: Maximum Observed Concentration (Cmax) of PF-07817883 | 53160 ± 21 |
Tmax of PF-07817883 was reported in this outcome measure.
| Hours | PF-07817883 6000 mg (Suspension), Fasted |
|---|---|
| Part 6: Time for Cmax (Tmax) of PF-07817883 | 1.00 (0.567 to 1.50) |
AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.
| Nanogram*hour/milliliter (ng*hr/mL) | PF-07817883 6000 mg (Suspension), Fasted |
|---|---|
| Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883 | 248300 ± 17 |
AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.
| Nanogram*hour/milliliter (ng*hr/mL) | PF-07817883 6000 mg (Suspension), Fasted |
|---|---|
| Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883 | 253000 ± 17 |
t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.
| Hours | PF-07817883 6000 mg (Suspension), Fasted |
|---|---|
| Part 6: Terminal Half-Life (t1/2) of PF-07817883 | 12.64 ± 7.1787 |
Collected over Part 1 and Part 6: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 and 52 days respectively); Part 2 and Part 5: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 and 65 days respectively); Part 3 and Part 4: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 and 47 days respectively). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo (Suspension), Fasted | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Part 1: Placebo (Suspension), Fed | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part 1: PF-07817883 150 mg (Suspension), Fasted | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1: PF-07817883 500 mg (Suspension), Fasted | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: PF-07817883 500 mg (Suspension), Fed | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part 1: PF-07817883 1500 mg (Suspension), Fasted | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1: PF-07817883 3000 mg (Suspension), Fasted | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Part 1: PF-07817883 4000 mg (Suspension), Fasted | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Part 2: Placebo (Suspension) BID, Fasted | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part 2: Placebo (Suspension) BID, Fasted, Chinese | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 3: PF-07817883 600 mg (Suspension), Fasted | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 4: PF-07817883 600 mg (Suspension), Fasted | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 5: PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Part 5: Midazolam 5 mg | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Part 6: Placebo (Suspension), Fasted | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Part 6: PF-07817883 6000 mg (Suspension), Fasted | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Part 6: Moxifloxacin 400 mg, Fasted | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Event | Part 1: Placebo (Suspension), Fasted | Part 1: Placebo (Suspension), Fed | Part 1: PF-07817883 150 mg (Suspension), Fasted | Part 1: PF-07817883 500 mg (Suspension), Fasted | Part 1: PF-07817883 500 mg (Suspension), Fed | Part 1: PF-07817883 1500 mg (Suspension), Fasted | Part 1: PF-07817883 3000 mg (Suspension), Fasted | Part 1: PF-07817883 4000 mg (Suspension), Fasted | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: PF-07817883 600 mg (Suspension), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted | Part 3: PF-07817883 SDD 600 mg (Tablet), Fed | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted | Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg | Part 5: Midazolam 5 mg | Part 6: Placebo (Suspension), Fasted | Part 6: PF-07817883 6000 mg (Suspension), Fasted | Part 6: Moxifloxacin 400 mg, Fasted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 0/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 9/13 | 9/13 | 0/23 | 0/23 | 0/24 |
| HaematomaVascular disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 2/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| Upper respiratory tract infectionInfections and infestations | 0/10 | 1/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 0/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 2/6 | 1/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| ConstipationGastrointestinal disorders | 2/10 | 0/2 | 0/6 | 1/6 | 0/4 | 2/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 0/3 | 0/12 | 1/12 | 0/6 | 1/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| DiarrheaGastrointestinal disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 2/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 0/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 1/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 1/3 | 0/12 | 0/12 | 0/6 | 0/12 | 1/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| Defaecation urgencyGastrointestinal disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 1/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| VomitingGastrointestinal disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 1/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| HypoaesthesiaNervous system disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 0/4 | 0/4 | 0/4 | 0/1 | 1/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
| GlossodyniaGastrointestinal disorders | 0/10 | 0/2 | 0/6 | 0/6 | 0/4 | 0/6 | 0/5 | 0/5 | 0/6 | 1/4 | 0/4 | 0/4 | 0/1 | 0/3 | 0/12 | 0/12 | 0/6 | 0/12 | 0/6 | 0/6 | 0/13 | 0/13 | 0/23 | 0/23 | 0/24 |
Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.
| Age, Customized(Participants) | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-44 Years | 0 | 1 | 1 | 2 | 1 | 1 | 2 | 5 | 2 | 4 | 2 | 0 | 3 | 2 | 0 | 1 | 1 | 2 | 2 | 4 | 4 | 3 | 3 | 4 | 4 | 3 | 3 | 4 | 64 |
| 45-60 Years | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 2 | 3 | 4 | 1 | 0 | 0 | 1 | 1 | 0 | 29 |
| Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sex/Gender, Customized(Participants) | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 19 |
| Male | 1 | 2 | 1 | 2 | 1 | 2 | 3 | 6 | 4 | 2 | 4 | 0 | 3 | 1 | 2 | 0 | 1 | 0 | 2 | 6 | 5 | 5 | 4 | 3 | 3 | 3 | 4 | 4 | 74 |
| Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 4 | 1 | 0 | 1 | 0 | 1 | 1 | 19 |
| Black or African American | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 3 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 3 | 0 | 1 | 31 |
| White | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 1 | 3 | 3 | 2 | 1 | 2 | 2 | 1 | 3 | 2 | 39 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast | P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast | P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast | P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed | P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed | P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed | Part 2: Placebo (Suspension) BID, Fasted | Part 2: PF-07817883 200 mg (Suspension) BID, Fasted | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted | Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted | Part 2: Placebo (Suspension) BID, Fasted, Chinese | Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese | Part 3: Treatment Sequence ABCD | Part 3: Treatment Sequence BCAD | Part 3: Treatment Sequence CABD | Part 3: Treatment Sequence BACE | Part 3: Treatment Sequence ACBE | Part 3: Treatment Sequence CBAE | Part 4: PF-07817883 600 mg (Suspension), Fasted | Part 5: Treatment Sequence AB | Part 5: Treatment Sequence BA | Part 6: Treatment Sequence ABC | Part 6: Treatment Sequence BCA | Part 6: Treatment Sequence CAB | Part 6: Treatment Sequence BAC | Part 6: Treatment Sequence ACB | Part 6: Treatment Sequence CBA | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 3 | 1 | 0 | 3 | 2 | 2 | 2 | 2 | 33 |
| Not Hispanic or Latino | 1 | 1 | 1 | 1 | 0 | 1 | 3 | 2 | 2 | 4 | 4 | 0 | 3 | 2 | 2 | 0 | 1 | 2 | 2 | 5 | 4 | 6 | 4 | 1 | 2 | 2 | 2 | 2 | 60 |
| Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2022 to primary completion in Sep 2023, 10 months.
Results were first posted in Nov 2024, 1 year 2 months after primary completion.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 10 months is above that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuzatrelvir · Midazolam